Literature DB >> 1902110

Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual.

R S Marshall1, M C Paterson, A M Rauth.   

Abstract

The mechanism of aerobic resistance to the quinone-containing anti-tumour agents mitomycin C (MMC) and porfiromycin (PM) has been investigated using non-transformed human cells. One of the cell strains used (3437T) was derived from an afflicted member of a cancer-prone family. This cell strain had been shown previously to be six times more resistant to the cytotoxic effects of these agents under aerobic but not hypoxic conditions when compared to a cell strain derived from an unrelated, normal donor (GM38). Differences could not be detected in the ability of cell sonicates prepared from either cell strain to produce alkylating species under aerobic conditions using a 4-(p-nitrobenzyl)pyridine assay. However, using 3H-labelled PM to monitor rapid drug uptake and subsequent accumulation due to drug metabolism, results were obtained indicating that the resistant cell strain (3437T) was deficient in an enzymatic pathway capable of metabolizing these compounds under aerobic but not hypoxic conditions. Dicumarol, an inhibitor of the quinone reductase DT-diaphorase (EC 1.6.99.2), decreased aerobic drug accumulation and cytotoxicity in the control cell strain, but did not alter the lack of accumulation noted in the resistant cell strain. Under hypoxic conditions, dicumarol increased cytotoxicity and drug accumulation in both cell strains. The mechanism of this enhanced cytotoxicity remains unclear. These results suggested that the resistant cells were deficient in the enzyme DT-diaphorase, a potential activator of PM. Enzymatic assays confirmed this and revealed no alterations in cytochrome P450 reductase (EC 1.6.2.4) activity or glutathione content. No protein characteristic of DT-diaphorase was detected in the resistant cell strain using a polyclonal rabbit-anti-rat antibody raised against this enzyme. Southern blot analysis using a rat DT-diaphorase cDNA probe demonstrated differences between the normal and resistant cell strains in the restriction fragment patterns. The present results are consistent with the hypothesis that decreased DT-diaphorase levels are causally associated with PM and MMC resistance in these cells under aerobic exposure conditions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902110     DOI: 10.1016/0006-2952(91)90108-h

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 2.  Cellular pharmacology of quinone bioreductive alkylating agents.

Authors:  S Rockwell; A C Sartorelli; M Tomasz; K A Kennedy
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

3.  Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs.

Authors:  Ryan G Snodgrass; Abby C Collier; Amy E Coon; Chris A Pritsos
Journal:  J Biol Chem       Date:  2010-04-23       Impact factor: 5.157

4.  Development and initial characterization of a mitomycin C-resistant colon cancer cell line variant.

Authors:  R R Perry; B R Greaves; Y Kang
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C.

Authors:  E Kobayashi; M Okabe; M Kono; H Arai; M Kasai; K Gomi; J H Lee; M Inaba; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C.

Authors:  D Ross; D Siegel; H Beall; A S Prakash; R T Mulcahy; N W Gibson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 7.  Cellular approaches to bioreductive drug mechanisms.

Authors:  A M Rauth; R S Marshall; B L Kuehl
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 8.  NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.

Authors:  David Siegel; Chao Yan; David Ross
Journal:  Biochem Pharmacol       Date:  2011-12-24       Impact factor: 6.100

9.  Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase).

Authors:  R D Traver; D Siegel; H D Beall; R M Phillips; N W Gibson; W A Franklin; D Ross
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Hyperresistance to 4-nitroquinoline 1-oxide cytotoxicity and reduced DNA damage formation in dermal fibroblast strains derived from five members of a cancer-prone family.

Authors:  R Mirzayans; M Sabour; A M Rauth; M C Paterson
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.